Celea Therapeutics
3 known investors
Find your way into Celea Therapeutics
Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.
Investors · 3
Funding
SEC filings, press & company announcements$180M disclosed across 1 of 2 rounds · 2026
- $180MraisedJul 2026 · 3 sources
Leaps by Bayer, PureTech Health, RA Capital Management
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
PureTech's Celea Raises $180m and Doses First Phase 3 Patient in IPF Trialkalkine.co.uk · Aug 2026Frequently asked questions
- What does Celea Therapeutics do?
- Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.
- Who are Celea Therapeutics's investors?
- Celea Therapeutics's investors include RA Capital, Leaps by Bayer, PureTech Health.
- How much funding has Celea Therapeutics raised?
- Celea Therapeutics has disclosed $180M raised across 1 of its 2 known rounds.